Bioinformatics/NNS
Interpretation/NN
of/IN
Exome/NN
Sequencing/NN
:/:
Blood/NN
Cancer/NN
./.
====================
We/PRP
had/VBD
analyzed/VBN
10/CD
exome/JJ
sequencing/NN
data/NNS
and/CC
single/JJ
nucleotide/NN
polymorphism/NN
chips/NNS
for/IN
blood/NN
cancer/NN
provided/VBD
by/IN
the/DT
PGM21/NN
(/(
The/DT
National/JJ
Project/JJ
for/IN
Personalized/JJ
Genomic/JJ
Medicine/NN
)/)
Award/JJ
program/NN
./.
====================
We/PRP
had/VBD
removed/VBN
sample/JJ
G06/NN
because/IN
the/DT
pair/NN
is/VBZ
not/RB
correct/VB
and/CC
G10/NN
because/IN
of/IN
possible/JJ
contamination/NN
./.
====================
In-house/RB
software/JJ
somatic/JJ
copy-number/NN
and/CC
heterozygosity/NN
alteration/NN
estimation/NN
(/(
SCHALE/NN
)/)
was/VBD
used/VBN
to/TO
detect/VB
one/CD
loss/NN
of/IN
heterozygosity/NN
region/NN
in/IN
G05/NN
./.
====================
We/PRP
had/VBD
discovered/VBN
27/CD
functionally/RB
important/JJ
mutations/NNS
./.
====================
Network/NN
and/CC
pathway/NN
analyses/NNS
gave/VBD
us/PRP
clues/NNS
that/IN
NPM1/NN
,/,
GATA2/NN
,/,
and/CC
CEBPA/NN
were/VBD
major/JJ
driver/RB
genes/NNS
./.
====================
By/IN
comparing/VBG
with/IN
previous/JJ
somatic/JJ
mutation/NN
profiles/NNS
,/,
we/PRP
had/VBD
concluded/VBN
that/IN
the/DT
provided/VBN
data/NNS
originated/VBN
from/IN
acute/JJ
myeloid/JJ
leukemia/NN
./.
====================
Protein/NN
structure/NN
modeling/VBG
showed/VBD
that/IN
somatic/JJ
mutations/NNS
in/IN
IDH2/NN
,/,
RASGEF1B/NN
,/,
and/CC
MSH4/NN
can/MD
affect/VB
protein/NN
structures/NNS
./.
====================
Thanks/NNS
to/TO
the/DT
next-generation/NN
sequencing/NN
(/(
NGS/NN
)/)
technology/NN
,/,
genomics/NNS
research/NN
area/NN
has/VBZ
been/VBN
developed/VBN
dramatically/RB
in/IN
recent/JJ
years/NNS
./.
====================
Since/IN
2008/CD
,/,
many/JJ
efforts/NNS
have/VBP
been/VBN
made/VBN
to/TO
find/VB
somatic/JJ
mutations/NNS
in/IN
cancer/NN
genomes/NNS
;/:
hundreds/VBZ
of/IN
samples/NNS
by/IN
exome/JJ
sequencing/NN
have/VBP
been/VBN
used/VBN
to/TO
develop/VB
diagnosis/NN
and/CC
prognosis/NN
markers/NNS
in/IN
various/JJ
cancers/NNS
in/IN
recent/JJ
researches/NNS
./.
====================
Cheaper/NN
price/RB
has/VBZ
enabled/VBN
us/PRP
to/TO
get/VB
more/RBR
exome/JJ
sequencing/NN
data/NNS
from/IN
hundreds/VBZ
of/IN
samples/NNS
,/,
even/RB
thousands/VBZ
of/IN
genomes/NNS
./.
====================
By/IN
applying/VBG
exome/JJ
sequencing/NN
to/TO
cancer/NN
genomes/NNS
,/,
we/PRP
can/MD
discover/VB
somatic/JJ
mutations/NNS
and/CC
somatic/JJ
copy-number/NN
alterations/NNS
(/(
SCNAs/NNS
)/)
on/IN
a/DT
massive/JJ
and/CC
genome-wide/NN
scale/NN
./.
====================
Traditionally/RB
,/,
array-based/VBN
comparative/JJ
genomic/JJ
hybridization/NN
has/VBZ
been/VBN
used/VBN
to/TO
discover/RB
SCNA/NN
,/,
but/CC
exome/JJ
sequencing/NN
has/VBZ
many/JJ
advantages/NNS
,/,
in/IN
that/DT
one/CD
can/MD
derive/VB
various/JJ
results/NNS
,/,
such/JJ
as/IN
somatic/JJ
mutations/NNS
,/,
loss/NN
of/IN
heterozygosity/NN
(/(
LOH/NN
)/)
,/,
and/CC
SCNA/NN
./.
====================
It/PRP
is/VBZ
still/RB
under/IN
debate/NN
because/IN
bioinformatics/NNS
methods/NNS
could/MD
give/VB
different/JJ
results/NNS
depending/VBG
on/IN
their/PRP$
parameters/NNS
and/CC
software/JJ
,/,
but/CC
major/JJ
driver/RB
genes/NNS
of/IN
somatic/JJ
mutations/NNS
show/VBP
a/DT
similar/JJ
consensus/NN
./.
====================
We/PRP
had/VBD
used/VBN
an/DT
in-house/JJ
bioinformatics/NNS
pipeline/NN
and/CC
databases/NNS
for/IN
this/DT
research/NN
,/,
especially/RB
``/NN
somatic/JJ
copy-number/NN
and/CC
heterozygosity/NN
alteration/NN
estimation/NN
''/CD
(/(
SCHALE/NN
)/)
to/TO
find/VB
LOH/NN
and/CC
SCNA/NN
./.
====================
Furthermore/RB
,/,
driver/RB
genes/NNS
were/VBD
also/RB
inferred/VBD
from/IN
network/NN
and/CC
pathway/NN
analyses/NNS
./.
====================
Protein/NN
structure/NN
prediction/NN
was/VBD
used/VBN
to/TO
predict/VB
putative/JJ
structural/JJ
changes/NNS
by/IN
somatic/JJ
mutations/NNS
and/CC
also/RB
possibly/RB
their/PRP$
functional/JJ
changes/NNS
./.
====================
Dataset/NN
====================
Whole-exome/DT
sequencing/NN
data/NNS
of/IN
tumor/normal/JJ
paired/JJ
samples/NNS
from/IN
10/CD
individuals/NNS
with/IN
blood/NN
cancer/NN
were/VBD
obtained/VBN
in/IN
FASTQ/NN
format/IN
from/IN
PGM21/NN
(/(
The/DT
National/JJ
Project/JJ
for/IN
Personalized/JJ
Genomic/JJ
Medicine/NN
)/)
./.
====================
For/IN
10/CD
of/IN
the/DT
samples/NNS
,/,
the/DT
genotype/NN
information/NN
from/IN
single/JJ
nucleotide/NN
poymorphism/NN
(/(
SNP/NN
)/)
chip/NN
was/VBD
additionally/RB
obtained/VBN
(/(
but/CC
not/RB
the/DT
raw/NN
data/NNS
)/)
./.
====================
Data/NNS
processing/NN
and/CC
quality/NN
control/NN
(/(
QC/NN
)/)
====================
The/DT
QC/NN
of/IN
sequencing/NN
reads/VBZ
was/VBD
performed/VBN
with/IN
NGS/NN
QC/NN
Toolkit/NN
,/,
and/CC
the/DT
high-quality/JJ
reads/VBZ
were/VBD
aligned/VBN
to/TO
the/DT
human/JJ
reference/NN
genome/NN
(/(
hg19/NN
,/,
http/NN
:/:
//genome.ucsc.edu/FW
)/)
using/VBG
BWA/NN
(/(
http/NN
:/:
//bio-bwa.sourceforge.net//JJ
)/)
[/(
1/CD
]/)
with/IN
default/NN
parameteres/NNS
./.
====================
Picard/NN
(/(
http/NN
:/:
//picard.sourceforge.net/JJ
)/)
was/VBD
used/VBN
to/TO
remove/VB
PCR/NN
duplicates/NNS
./.
====================
Base/NN
quality/NN
recalibration/NN
and/CC
local/JJ
realignment/NN
around/IN
indels/VBZ
were/VBD
performed/VBN
using/VBG
Genome/NN
Analysis/NN
Toolkit/NN
(/(
GATK/NN
,/,
http/NN
:/:
//www.broadinstitute.org/gatk//JJ
)/)
./.
====================
Because/IN
our/PRP$
previous/JJ
study/NN
showed/VBD
that/IN
the/DT
discordance/NN
of/IN
indel/NN
alignments/NNS
had/VBD
potential/JJ
to/TO
generate/VB
false-positive/JJ
somatic/JJ
mutations/NNS
,/,
we/PRP
performed/VBD
the/DT
local/JJ
realignment/JJ
after/IN
the/DT
merging/JJ
of/IN
alignments/NNS
from/IN
same/JJ
patients/NNS
./.
====================
Template/JJ
lengths/NNS
were/VBD
calculated/VBN
using/VBG
the/DT
processed/VBN
alignments/NNS
,/,
and/CC
the/DT
distributions/NNS
for/IN
each/DT
samples/NNS
were/VBD
plotted/VBN
to/TO
examine/VB
the/DT
qualities/NNS
of/IN
sequencing/NN
libraries/NNS
./.
====================
Variant/JJ
genotyping/VBG
for/IN
each/DT
sample/JJ
was/VBD
performed/VBN
with/IN
UnifiedGenotyper/JJ
of/IN
GATK/NN
,/,
and/CC
the/DT
variants/NNS
were/VBD
filtered/VBN
as/IN
follows/VBZ
:/:
mapping/VBG
quality/NN
zero/CD
(/(
MQ0/NNP
)/)
≥/RB
4/CD
&/CC
&/CC
MQ0/depth/NNP
of/IN
coverage/JJ
(/(
DP/NN
)/)
>/JJR
0.1/CD
,/,
variation/NN
quality/RB
(/(
QUAL/NN
)/)
</JJR
200/CD
,/,
quality/RB
by/IN
depth/DT
(/(
QD/NNP
)/)
</JJR
5/CD
,/,
Fisher/RB
strand/CC
(/(
FS/NNP
)/)
>/JJR
60/CD
,/,
MQ/NNP
</JJR
40/CD
,/,
DP/NN
</JJR
10/CD
(/(
5/CD
if/IN
no/DT
variant/JJ
allele/NN
)/)
,/,
genotype/JJ
quality/NN
(/(
GQ/NNP
)/)
</JJR
13/CD
./.
====================
The/DT
genomic/JJ
annotation/NN
of/IN
variants/NNS
was/VBD
performed/VBN
with/IN
custom-made/NN
scripts/NNS
and/CC
refSeq/NN
information/NN
./.
====================
Identification/NN
of/IN
somatic/JJ
mutations/NNS
====================
We/PRP
had/VBD
developed/VBN
a/DT
bioinformatics/NNS
pipeline/NN
for/IN
this/DT
award/NN
program/NN
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
VarScan/NN
[/(
2/CD
]/)
was/VBD
used/VBN
to/TO
identify/VB
somatic/JJ
mutations/NNS
./.
====================
The/DT
output/JJ
of/IN
VarScan/JJ
was/VBD
filtered/VBN
as/IN
follows/VBZ
:/:
somatic/JJ
p-value/NN
≤/CD
0.05/CD
,/,
normal/JJ
allele/NN
depth/NN
≤/CD
1/CD
,/,
tumor/NN
allele/NN
depth/NN
≥/CD
5/CD
,/,
tumor/NN
total/JJ
depth/NN
≥/CD
10/CD
./.
====================
The/DT
mutation/NN
set/NN
was/VBD
annotated/VBN
using/VBG
a/DT
custom-made/JJ
script/NN
with/IN
refSeq/JJ
,/,
SIFT/NN
(/(
http/NN
:/:
//sift.jcvi.org//JJ
)/)
,/,
MutationAssessor/NN
,/,
phyloP46way/NN
(/(
vertebrate/RB
)/)
,/,
dbSNP/NN
137/CD
[/(
3/CD
]/)
,/,
in-house/RB
Korean/JJ
variation/NN
database/NN
,/,
etc/JJ
./.
====================
We/PRP
selected/VBD
the/DT
driver/RB
mutations/NNS
that/IN
were/VBD
not/RB
in/IN
dbSNP/NN
137/CD
,/,
excluding/VBG
clinically/RB
associated/VBN
variants/NNS
(/(
Flagged/JJ
track/VBP
in/IN
University/JJ
of/IN
California/NN
Santa/NN
Cruz/NN
[/(
UCSC/NN
]/)
Genome/NN
Browser/NN
)/)
and/CC
an/DT
in-house/JJ
Korean/JJ
variation/NN
database/NN
,/,
and/CC
were/VBD
deleterious/JJ
missense/NN
,/,
nonsense/JJ
,/,
read-through/IN
,/,
splicesite/NN
,/,
or/CC
coding/VBG
indel/NN
mutations/NNS
(/(
NS/SS/I/NN
)/)
./.
====================
The/DT
deleterious/JJ
missense/NN
mutations/NNS
were/VBD
determined/VBN
if/IN
at/IN
least/JJS
2/CD
out/RP
of/IN
the/DT
following/VBG
3/CD
were/VBD
true/JJ
:/:
PhyloP/NN
score/RB
>/JJR
1.5/CD
,/,
SIFT/NN
prediction/NN
=/JJ
deleterious/JJ
,/,
MutationAssessor/NN
Func/NN
./.
====================
Impact/NN
=/JJ
high/JJ
or/CC
medium/NN
./.
====================
The/DT
total/JJ
numbers/NNS
of/IN
candidates/NNS
for/IN
each/DT
filtering/VBG
step/NN
are/VBP
summarized/VBN
in/IN
Fig/NN
./.
====================
1/CD
./.
====================
We/PRP
found/VBD
somatic/JJ
mutations/NNS
in/IN
samples/NNS
G10/NN
,/,
G08/NN
,/,
and/CC
G09/NN
,/,
but/CC
they/PRP
were/VBD
not/RB
NS/SS/I/NN
./.
====================
Comparison/NN
with/IN
genotypes/NNS
from/IN
SNP/NN
chip/NN
====================
To/TO
compare/VB
with/IN
genotypes/NNS
from/IN
SNP/NN
chip/NN
,/,
the/DT
genotyping/VBG
was/VBD
performed/VBN
using/VBG
UnifiedGenotyper/JJ
with/IN
the/DT
intervals/NNS
,/,
including/VBG
all/DT
the/DT
coordinates/NNS
of/IN
SNP/NN
chip/NN
and/CC
the/DT
option-output_mode/NN
EMIT_ALL_SITES/NN
./.
====================
For/IN
each/DT
sample/NN
with/IN
genotype/NN
information/NN
from/IN
SNP/NN
chip/NN
,/,
overall/JJ
genotype/NN
concordance/NN
,/,
non-reference/RB
sensitivity/NN
,/,
and/CC
non-reference/NN
discrepancy/NN
rate/NN
were/VBD
calculated/VBN
according/VBG
to/TO
the/DT
guide/NN
of/IN
GATK/NN
VariantEval/JJ
using/VBG
the/DT
genotypes/NNS
with/IN
DP/NN
≥/CD
5/CD
./.
====================
Genotype/NN
comparison/NN
of/IN
samples/NNS
====================
The/DT
multi-sample/JJ
SNP/NN
genotyping/VBG
was/VBD
performed/VBN
with/IN
UnifiedGenotyper/JJ
to/TO
compare/VB
the/DT
genotypes/NNS
on/IN
the/DT
variant/JJ
positions/NNS
where/WRB
all/DT
samples/NNS
were/VBD
able/JJ
to/TO
be/VB
genotyped/VBN
./.
====================
The/DT
filtration/NN
scheme/NN
was/VBD
the/DT
same/JJ
as/IN
above/JJ
./.
====================
The/DT
distance/NN
between/IN
two/CD
samples/NNS
was/VBD
calculated/VBN
as/IN
the/DT
sum/NN
of/IN
genotype/JJ
difference/NN
values/NNS
(/(
0/CD
if/IN
two/CD
genotypes/NNS
are/VBP
same/JJ
,/,
1/CD
if/IN
a/DT
genotype/JJ
is/VBZ
0/1/CD
and/CC
another/DT
is/VBZ
0/0/CD
or/CC
1/1/CD
,/,
2/CD
if/IN
a/DT
genotype/JJ
is/VBZ
0/0/CD
and/CC
another/DT
is/VBZ
1/1/CD
)/)
./.
====================
The/DT
distances/NNS
were/VBD
divided/VBN
by/IN
the/DT
number/NN
of/IN
the/DT
variant/JJ
positions/NNS
./.
====================
Heatmap/RB
and/CC
similarity/NN
matrix/NN
were/VBD
used/VBN
to/TO
visualize/VB
the/DT
distances/NNS
./.
====================
Genome/NN
annotation/NN
====================
We/PRP
used/VBD
in-house/IN
genome/NN
annotation/NN
pipelines/NNS
and/CC
various/JJ
databaes/NNS
,/,
as/IN
summarized/VBN
below/IN
./.
====================
Genomic/JJ
annotation/NN
:/:
refGene/JJ
====================
Human/JJ
Genome/NN
Variation/NN
Society/NN
(/(
HGVS/NN
)/)
nomenclature/NN
:/:
nucleotide/NN
(/(
non-coding/JJ
,/,
coding/VBG
)/)
,/,
protein/NN
====================
SIFT/NN
-/:
tolerant/JJ
amino/NN
acid/NN
substitutions/NNS
====================
MutationAssessor/NN
====================
phyloP46way_vertebrate/NN
====================
GERP/NN
;/:
GERP_element/JJ
:/:
rsScore/RB
====================
RepeatMasker/NN
====================
Tandem/JJ
repeat/NN
definition/NN
====================
dbSNP/NN
137/CD
;/:
Common/JJ
,/,
Flagged/JJ
,/,
Mult/JJ
====================
Korean/NN
variation/NN
database/NN
(/(
54/CD
Personal/JJ
Genomes/NNS
)/)
====================
OMIM/NN
morbid/JJ
genes/NNS
====================
Oncogenes/NNS
and/CC
tumor/NN
suppressors/NNS
from/IN
Ariadne/NN
Pathway/NN
Studio/NN
====================
Detection/NN
of/IN
LOH/NN
and/CC
SCNA/NN
by/IN
SCHALE/NN
====================
Detection/NN
LOH/NN
and/CC
SCNA/NN
was/VBD
performed/VBN
with/IN
custom-made/NN
software/JJ
SCHALE/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
For/IN
the/DT
positions/NNS
where/WRB
the/DT
genotypes/NNS
were/VBD
heterozygous/JJ
in/IN
normal/JJ
samples/NNS
,/,
the/DT
values/NNS
of/IN
LOH/NN
and/CC
SCNA/NN
were/VBD
calculated/VBN
./.
====================
The/DT
values/NNS
of/IN
LOH/NN
were/VBD
calculated/VBN
by/IN
the/DT
equation/NN
:/:
====================
LOH/NN
=/JJ
|/CD
RT/NN
-/:
0.5/CD
|/NN
-/:
|/CD
RN/NN
-/:
0.5/CD
|/NN
,/,
where/WRB
RN/NN
is/VBZ
the/DT
count/NN
of/IN
reads/VBZ
supporting/VBG
a/DT
non-reference/JJ
allele/NN
divided/VBN
by/IN
the/DT
total/JJ
depth/NN
in/IN
the/DT
normal/JJ
sample/JJ
and/CC
RT/NN
is/VBZ
in/IN
tumor/NN
sample/NN
./.
====================
The/DT
values/NNS
of/IN
SCNA/NN
were/VBD
calculated/VBN
by/IN
the/DT
equation/NN
:/:
====================
SCNA/NN
=/JJ
log2/NN
(/(
tumor/NN
depth/normal/JJ
depth/NN
)/)
,/,
where/WRB
the/DT
depths/NNS
were/VBD
normalized/VBN
using/VBG
R/NN
library/NN
tweeDEseq/JJ
./.
====================
The/DT
values/NNS
of/IN
LOH/NN
and/CC
SCNA/NN
were/VBD
segmented/VBN
together/RB
using/VBG
R/NN
library/NN
DNAcopy/JJ
with/IN
the/DT
parameters/NNS
alpha/NN
=/JJ
0.01/CD
and/CC
undo.SD/NN
=/JJ
2/CD
./.
====================
The/DT
segments/NNS
and/CC
values/NNS
were/VBD
plotted/VBN
for/IN
each/DT
chromosome/NN
with/IN
the/DT
idiograms/NNS
in/IN
R/NN
library/NN
SNPchip/NN
./.
====================
Network/NN
analysis/NN
====================
Ingenuity/NN
Pathway/NN
Analysis/NN
(/(
IPA/NN
)/)
was/VBD
used/VBN
to/TO
perform/VB
the/DT
network/NN
study/NN
of/IN
the/DT
identified/VBN
somatically/RB
mutated/VBN
genes/NNS
and/CC
the/DT
genes/NNS
in/IN
the/DT
LOH/NN
region/NN
./.
====================
Protein/NN
structure/NN
modeling/VBG
====================
Before/IN
the/DT
structural/JJ
modeling/VBG
,/,
the/DT
protein/NN
features/NNS
related/JJ
to/TO
the/DT
somatic/JJ
mutations/NNS
were/VBD
found/VBN
by/IN
BLAST/NN
on/IN
UniProt/JJ
(/(
10/CD
most/JJS
similar/JJ
proteins/NNS
,/,
expectation/NN
value/NN
=/JJ
1e-30/CD
)/)
and/CC
residue/NN
mapping/VBG
./.
====================
Homology/NN
modeling/VBG
was/VBD
performed/VBN
using/VBG
MODELLER/NN
(/(
http/NN
:/:
//salilab.org/modeller/JJR
)/)
with/IN
the/DT
templates/NNS
1LWD/NN
for/IN
IDH2/NN
,/,
3KSY/NN
for/IN
RASGEF1B/NN
,/,
and/CC
2O8B/NN
for/IN
MSH4/NN
./.
====================
Molecular/JJ
dynamics/NNS
simulation/NN
was/VBD
performed/VBN
with/IN
GROMACS/NN
(/(
http/NN
:/:
//pubs.acs.org/doi/abs/10.1021/ct700301q/NN
)/)
./.
====================
The/DT
structural/JJ
images/NNS
were/VBD
drawn/VBN
using/VBG
PyMOL/NN
(/(
http/NN
:/:
//www.pymol.org//JJ
)/)
./.
====================
QC/NN
and/CC
results/VBZ
====================
We/PRP
had/VBD
used/VBN
several/JJ
methods/NNS
to/TO
check/VB
the/DT
qualities/NNS
of/IN
sequence/NN
reads/VBZ
./.
====================
First/RB
,/,
we/PRP
used/VBD
NGS/NN
QC/NN
Tools/NNS
[/(
4/CD
]/)
to/TO
confirm/VB
sequence/NN
qualities/NNS
(/(
Supplementary/JJ
Table/JJ
1/CD
)/)
./.
====================
Overall/RB
,/,
they/PRP
had/VBD
a/DT
very/RB
good/JJ
quality/NN
,/,
according/VBG
to/TO
NGS/NN
QC/NN
Tools/NNS
results/NNS
./.
====================
Template/JJ
length/NN
(/(
library/NN
size/NN
)/)
was/VBD
also/RB
evenly/RB
distributed/VBN
for/IN
all/DT
samples/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Reference/NN
genome/NN
mapping/NN
====================
About/RB
98/CD
%/NN
of/IN
reads/VBZ
were/VBD
mapped/VBN
onto/IN
the/DT
human/JJ
reference/NN
genome/NN
(/(
UCSC/NN
Genome/NN
Browser/NN
,/,
hg19/NN
)/)
,/,
summarized/VBD
in/IN
Supplementary/JJ
Table/JJ
2/CD
./.
====================
After/IN
a/DT
duplicate/JJ
removal/NN
step/NN
,/,
77.85/CD
%/NN
reads/VBZ
were/VBD
retained/VBN
;/:
each/DT
sample/NN
had/VBD
up/RB
to/TO
25/CD
%/NN
duplicates/VBZ
./.
====================
Eighty-nine/CD
percent/NN
of/IN
target/NN
areas/NNS
covered/VBD
at/IN
least/JJS
10/CD
sequence/NN
reads/VBZ
,/,
which/WDT
is/VBZ
sufficient/JJ
for/IN
discovering/VBG
somatic/JJ
mutations/NNS
./.
====================
We/PRP
did/VBD
not/RB
get/VB
target/NN
enrichment/JJ
kit/NN
information/NN
from/IN
PGM21/NN
,/,
so/RB
we/PRP
had/VBD
compared/VBN
coverage/NN
information/NN
from/IN
several/JJ
kits/NNS
and/CC
concluded/VBD
that/IN
SureSelect/NN
All/DT
Exon/NN
50Mb/JJ
was/VBD
used/VBN
for/IN
exome/JJ
sequencing/NN
./.
====================
Genotyping/VBG
by/IN
GATK/NN
and/CC
comparison/NN
with/IN
SNP/NN
chip/NN
====================
In/IN
order/NN
to/TO
check/VB
the/DT
genotyping/VBG
parameters/NNS
we/PRP
had/VBD
used/VBN
,/,
10/CD
SNP/NN
chip/NN
results/NNS
were/VBD
compared/VBN
./.
====================
Because/IN
SNP/NN
chip/NN
data/NNS
were/VBD
genotypes/NNS
,/,
we/PRP
could/MD
not/RB
infer/VB
copy/NN
number/NN
changes/NNS
;/:
we/PRP
could/MD
only/RB
calculate/JJ
concordance/NN
between/IN
exome/JJ
sequencing/NN
and/CC
SNP/NN
chip/NN
./.
====================
We/PRP
had/VBD
used/VBN
a/DT
separate/JJ
bioinformatics/NNS
pipeline/NN
for/IN
checking/VBG
concordance/NN
,/,
and/CC
GATK/NN
[/(
5/CD
]/)
was/VBD
used/VBN
mainly/RB
for/IN
genotyping/VBG
of/IN
germline/NN
samples/NNS
./.
====================
We/PRP
had/VBD
discovered/VBN
18,500-19,200/CD
coding/VBG
SNPs/NNS
./.
====================
The/DT
number/NN
of/IN
SNPs/NNS
from/IN
the/DT
5/CD
'/``
untranslated/JJ
region/NN
(/(
UTR/NN
)/)
was/VBD
close/JJ
to/TO
that/DT
of/IN
the/DT
3/CD
'/``
UTR/NN
,/,
so/RB
the/DT
target/NN
enrichment/JJ
kit/NN
was/VBD
not/RB
the/DT
latest/JJ
3/CD
'/``
UTR/NN
extension/NN
version/NN
(/(
Supplementary/JJ
Table/JJ
3/CD
)/)
./.
====================
In/IN
general/JJ
,/,
the/DT
3/CD
'/``
UTR/NN
is/VBZ
much/RB
larger/JJR
than/IN
the/DT
5/CD
'/``
UTR/NN
;/:
a/DT
new/JJ
3/CD
'/``
UTR/NN
extension/NN
version/NN
of/IN
the/DT
exome/JJ
kit/NN
will/MD
give/VB
at/IN
least/JJS
a/DT
few/JJ
times/NNS
more/RBR
SNPs/NNS
than/IN
5/CD
'/``
UTR/NN
./.
====================
Two/CD
hundred/JJ
fifty/CD
coding/VBG
SNPs/NNS
were/VBD
retained/VBN
after/IN
removal/NN
of/IN
dbSNP137/NN
[/(
6/CD
]/)
and/CC
an/DT
in-house/JJ
Korean/JJ
database/NN
comprised/VBD
of/IN
54/CD
normal/JJ
individuals/NNS
./.
====================
Among/IN
them/PRP
,/,
we/PRP
can/MD
focus/VB
on/IN
about/RB
160/CD
variants/NNS
of/IN
NS/SS/I/NN
,/,
which/WDT
is/VBZ
believed/VBN
to/TO
be/VB
most/RBS
functionally/RB
important/JJ
(/(
Supplementary/JJ
Table/JJ
4/CD
)/)
./.
====================
Overall/RB
concordance/NN
was/VBD
at/IN
least/JJS
99.6/CD
%/NN
./.
====================
In/IN
recent/JJ
personal/JJ
genome/NN
papers/NNS
,/,
they/PRP
reported/VBD
more/RBR
than/IN
99.95/CD
%/NN
concordance/NN
between/IN
whole-genome/JJ
and/CC
SNP/NN
chips/NNS
./.
====================
Usually/RB
,/,
one/CD
can/MD
achieve/VB
higher/JJR
concordance/NN
if/IN
he/DT
uses/VBZ
strict/JJ
parameters/NNS
for/IN
their/PRP$
genotyping/VBG
./.
====================
Our/PRP$
purpose/NN
is/VBZ
to/TO
discover/JJ
somatic/JJ
mutations/NNS
,/,
not/RB
genotyping/VBG
of/IN
normal/JJ
germline/NN
,/,
so/RB
we/PRP
did/VBD
not/RB
put/VB
much/RB
effort/NN
to/TO
get/VB
higher/JJR
concordance/NN
values/NNS
./.
====================
Especially/RB
,/,
G10.N/NN
SNP/NN
chip/NN
data/NNS
were/VBD
totally/RB
different/JJ
from/IN
the/DT
exome/JJ
,/,
because/IN
only/RB
77/CD
%/NN
of/IN
SNPs/NNS
were/VBD
shared/VBN
(/(
Supplementary/JJ
Table/JJ
5/CD
)/)
./.
====================
As/IN
one/CD
can/MD
see/VB
in/IN
the/DT
table/JJ
,/,
77/CD
%/NN
means/NNS
they/PRP
are/VBP
different/JJ
individuals/NNS
(/(
false/VBP
positive/JJ
for/IN
Award/JJ
program/NN
)/)
./.
====================
Distance/NN
and/CC
similarity/NN
matrix/NN
were/VBD
calculated/VBN
to/TO
see/VB
the/DT
differences/NNS
and/CC
similarity/NN
(/(
Supplementary/JJ
Table/JJ
6/CD
,/,
Supplementary/JJ
Fig/NN
./.
====================
2/CD
)/)
./.
====================
We/PRP
had/VBD
concluded/VBN
that/IN
sample/NN
G06/NN
has/VBZ
a/DT
different/JJ
sample/NN
pair/NN
from/IN
different/JJ
individuals/NNS
./.
====================
G10/NN
also/RB
has/VBZ
only/RB
92/CD
%/NN
similarity/NN
and/CC
showed/VBD
a/DT
little/JJ
similarity/NN
between/IN
G03/NN
and/CC
G04/NN
./.
====================
For/IN
such/JJ
reasons/NNS
,/,
G10/NN
was/VBD
possibly/RB
contaminated/VBN
and/CC
therefore/RB
rejected/VBD
from/IN
our/PRP$
bioinformatics/NNS
analysis/NN
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
had/VBD
used/VBN
only/RB
8/CD
sample/NN
pairs/NNS
for/IN
discovery/NN
of/IN
somatic/JJ
mutations/NNS
,/,
LOH/NN
,/,
and/CC
SCNA/NN
./.
====================
A/DT
list/NN
of/IN
somatic/JJ
mutations/NNS
====================
After/IN
removal/NN
of/IN
SNPs/NNS
and/CC
indels/VBZ
from/IN
dbSNP137/NN
[/(
6/CD
]/)
and/CC
an/DT
in-house/JJ
Korean/JJ
database/NN
,/,
27/CD
somatic/JJ
mutations/NNS
(/(
NS/SS/I/NN
)/)
were/VBD
discovered/VBN
from/IN
8/CD
samples/NNS
./.
====================
Among/IN
them/PRP
,/,
NPM1/NN
showed/VBD
a/DT
TCTG/NN
internal/JJ
tandem/JJ
insertion/NN
./.
====================
NPM1-ITD/NN
is/VBZ
known/VBN
to/TO
be/VB
major/JJ
driver/RB
gene/NN
in/IN
acute/JJ
myeloid/JJ
leukemia/NN
(/(
AML/NN
)/)
(/(
Table/JJ
1/CD
,/,
Supplementary/JJ
Table/JJ
7/CD
)/)
./.
====================
NPM1-ITD/NN
and/CC
GATA2/NN
were/VBD
recurrently/RB
found/VBN
in/IN
two/CD
samples/NNS
./.
====================
We/PRP
had/VBD
removed/VBN
all/DT
variants/NNS
from/IN
dbSNP/NN
and/CC
an/DT
in-house/JJ
Korean/JJ
database/NN
that/DT
showed/VBD
polymorphisms/NNS
or/CC
normal/JJ
variants/NNS
,/,
because/IN
they/PRP
can/MD
be/VB
putatively/RB
functionally/RB
neutral/JJ
,/,
even/RB
if/IN
they/PRP
are/VBP
discovered/VBN
as/IN
somatic/JJ
mutations/NNS
./.
====================
We/PRP
had/VBD
downloaded/VBN
the/DT
COSMIC/NN
(/(
http/NN
:/:
//www.sanger.ac.uk/genetics/CGP/cosmic//JJ
)/)
database/NN
and/CC
compared/VBN
with/IN
our/PRP$
somatic/JJ
mutations/NNS
./.
====================
We/PRP
found/VBD
the/DT
same/JJ
highly/RB
recurrent/JJ
somatic/JJ
mutation/NN
variants/NNS
in/IN
four/CD
genes/NNS
:/:
NPM1/NN
,/,
IDH2/NN
,/,
CEBPA/NN
,/,
and/CC
GATA2/NN
./.
====================
In/IN
26/CD
genes/NNS
,/,
we/PRP
can/MD
easily/RB
see/VB
the/DT
NPM1/NN
,/,
IDH2/NN
,/,
GATA2/NN
,/,
CEBPA/NN
genes-known/VBN
to/TO
be/VB
highly/RB
mutated/VBN
in/IN
AML/NN
[/(
3/CD
]/)
./.
====================
Based/VBN
on/IN
the/DT
recent/JJ
somatic/JJ
mutation/NN
profiles/NNS
from/IN
exome/DT
sequencing/NN
,/,
one/CD
can/MD
see/VB
the/DT
following/VBG
trends/NNS
of/IN
them/PRP
./.
====================
In/IN
solid/JJ
tumors/NNS
,/,
somatic/JJ
mutation/NN
in/IN
TP53/NN
is/VBZ
high/JJ
./.
====================
But/CC
in/IN
melanoma/NN
,/,
BRAF/NN
mutation/NN
is/VBZ
high/JJ
./.
====================
In/IN
hepatocellular/JJ
carcinoma/NN
,/,
CTNNB1/NN
mutation/NN
is/VBZ
high/JJ
./.
====================
It/PRP
means/NNS
that/DT
somatic/JJ
mutations/NNS
can/MD
play/VB
a/DT
different/JJ
role/NN
,/,
depending/VBG
on/IN
cancer/NN
./.
====================
In/IN
AML/NN
,/,
other/JJ
than/IN
the/DT
well-known/JJ
TP53/NN
mutation/NN
,/,
genes/NNS
,/,
such/JJ
as/IN
FLT3/NN
,/,
TET2/NN
,/,
and/CC
NPM1/NN
,/,
show/VBP
somatic/JJ
mutations/NNS
and/CC
are/VBP
the/DT
driver/RB
genes/NNS
[/(
7/CD
]/)
./.
====================
Discovery/RB
of/IN
LOH/NN
and/CC
SCAN/NN
by/IN
SCHALE/NN
====================
We/PRP
had/VBD
used/VBN
SCHALE/NN
to/TO
discover/JJ
LOH/NN
and/CC
SCNA/NN
./.
====================
It/PRP
appears/VBZ
that/IN
sample/JJ
G06/NN
has/VBZ
many/JJ
LOHs/NNS
and/CC
SCNAs/NNS
,/,
but/CC
an/DT
incorrect/JJ
sample/NN
pair/NN
can/MD
give/VB
those/DT
results/NNS
(/(
Supplementary/JJ
Fig/NN
./.
====================
3/CD
)/)
./.
====================
We/PRP
also/RB
discovered/VBD
high/JJ
LOH/NN
on/IN
chrX/NN
in/IN
G10/NN
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
We/PRP
could/MD
not/RB
find/VB
any/DT
somatic/JJ
mutations/NNS
in/IN
G10/NN
./.
====================
Previously/RB
,/,
we/PRP
had/VBD
described/VBN
that/IN
it/PRP
could/MD
be/VB
contamination/NN
,/,
but/CC
another/DT
possibility/NN
is/VBZ
that/DT
they/PRP
are/VBP
exomes/VBZ
from/IN
identical/JJ
twins/NNS
with/IN
different/JJ
genders/NNS
(/(
we/PRP
do/VBP
not/RB
have/VB
any/DT
gender/JJ
information/NN
from/IN
any/DT
samples/NNS
)/)
./.
====================
Abnormal/JJ
regions/NNS
on/IN
chr1/NN
in/IN
G05/NN
showed/VBD
LOH/NN
in/IN
the/DT
germline/NN
,/,
but/CC
it/PRP
is/VBZ
quite/RB
unnatural/JJ
(/(
Fig/NN
./.
====================
4/CD
)/)
./.
====================
We/PRP
are/VBP
not/RB
describing/VBG
much/RB
for/IN
this/DT
area/NN
until/IN
experimental/JJ
validation/NN
is/VBZ
performed/VBN
./.
====================
We/PRP
had/VBD
found/VBN
one/CD
LOH/NN
region/NN
on/IN
chr13/NN
in/IN
G05/NN
(/(
Fig/NN
./.
====================
5/CD
)/)
./.
====================
INTS6/NN
and/CC
KIAA1704/NN
are/VBP
located/JJ
at/IN
both/CC
ends/NNS
and/CC
potentially/RB
could/MD
make/VB
a/DT
fusion/NN
gene/NN
(/(
Fig/NN
./.
====================
6/CD
)/)
./.
====================
Experimental/JJ
validation/NN
is/VBZ
also/RB
required/VBD
for/IN
this/DT
assumption/NN
./.
====================
INTS6/NN
is/VBZ
expressed/VBN
in/IN
blood/NN
;/:
many/JJ
expressed/VBN
sequence/NN
tags/NNS
(/(
ESTs/NNS
)/)
were/VBD
found/VBN
in/IN
INTS6/NN
in/IN
UniGene/JJ
(/(
http/NN
:/:
//www.ncbi.nlm.nih.gov/UniGene/JJ
)/)
./.
====================
But/CC
,/,
KIAA1704/NN
has/VBZ
a/DT
small/JJ
number/NN
of/IN
ESTs/NNS
,/,
so/RB
we/PRP
could/MD
not/RB
infer/VB
expression/NN
levels/NNS
from/IN
UniGene/JJ
./.
====================
There/EX
are/VBP
61/CD
genes/NNS
on/IN
chr13:45,578,409-52,035,344/NN
,/,
and/CC
we/PRP
had/VBD
an/DT
additional/JJ
set/NN
of/IN
network/NN
and/CC
pathway/NN
analyses/NNS
,/,
including/VBG
6/CD
genes/NNS
(/(
MAST2/NN
,/,
L1TD1/NN
,/,
MSH4/NN
,/,
GATA2/NN
,/,
VDAC2/NN
,/,
and/CC
PHF6/NN
)/)
with/IN
somatic/JJ
mutations/NNS
./.
====================
The/DT
top/NN
network/NN
is/VBZ
``/CD
Cancer/NN
,/,
Hematological/JJ
Disease/NN
,/,
Immunological/JJ
Disease/NN
,/,
''/NNP
comprised/VBD
of/IN
GATA2/NN
and/CC
MAST2/NN
./.
====================
Many/JJ
genes/NNS
in/IN
LOH/NN
regions/NNS
are/VBP
included/VBN
in/IN
this/DT
network/NN
./.
====================
We/PRP
can/MD
infer/VB
that/IN
those/DT
genes/NNS
with/IN
somatic/JJ
mutations/NNS
and/CC
LOH/NN
can/MD
interact/VB
with/IN
each/DT
other/JJ
(/(
Fig/NN
./.
====================
7/CD
)/)
./.
====================
Network/NN
and/CC
pathway/NN
analyses/NNS
====================
Using/VBG
26/CD
genes/NNS
,/,
we/PRP
had/VBD
used/VBN
IPA/NN
(/(
http/NN
:/:
//www.ingenuity.com//JJ
)/)
[/(
8/CD
]/)
for/IN
network/NN
and/CC
pathway/NN
analyses/NNS
./.
====================
It/PRP
can/MD
be/VB
summarized/VBN
in/IN
two/CD
major/JJ
networks/NNS
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
top/NN
network/NN
is/VBZ
``/CD
Cancer/NN
,/,
Hematologicial/JJ
Disease/NN
,/,
Cell/NN
Cycle/NN
,/,
''/NNP
and/CC
it/PRP
has/VBZ
NPM1/NN
,/,
GATA2/NN
,/,
and/CC
CEBPA/NN
genes/NNS
(/(
Figs/NNS
./.
====================
8/CD
and/CC
9/CD
)/)
./.
====================
These/DT
three/CD
genes/NNS
showed/VBD
a/DT
highly/RB
connected/VBN
network/NN
and/CC
well-known/JJ
major/JJ
driver/NN
genes/NNS
in/IN
leukemia/NN
./.
====================
The/DT
second/JJ
network/NN
is/VBZ
related/JJ
to/TO
cell/NN
death/NN
and/CC
survival/NN
(/(
Fig/NN
./.
====================
10/CD
)/)
./.
====================
IDH2/NN
and/CC
PHF6/NN
genes/NNS
were/VBD
located/JJ
in/IN
this/DT
network/NN
./.
====================
But/CC
overall/JJ
,/,
somatic/JJ
mutation/NN
frequency/NN
in/IN
the/DT
top/NN
network/NN
is/VBZ
much/RB
higher/JJR
than/IN
the/DT
second/JJ
network/NN
above/JJ
./.
====================
IPA/NN
analysis/NN
reports/NNS
are/VBP
summarized/VBN
in/IN
Supplementary/JJ
Table/JJ
8/CD
./.
====================
Protein/NN
structure/NN
modeling/VBG
====================
We/PRP
have/VBP
examined/VBN
protein/NN
features/NNS
related/JJ
to/TO
residues/NNS
substituted/VBD
by/IN
the/DT
identified/VBN
27/CD
somatic/JJ
mutations/NNS
and/CC
found/VBD
the/DT
features/NNS
of/IN
19/CD
mutations/NNS
(/(
Table/JJ
3/CD
)/)
./.
====================
The/DT
mutation/NN
of/IN
CEBPA/NN
generates/VBZ
a/DT
duplication/NN
of/IN
an/DT
amino/NN
acid/NN
that/IN
affects/VBZ
the/DT
original/JJ
helical/JJ
secondary/JJ
structure/NN
./.
====================
The/DT
residue/NN
corresponding/VBG
to/TO
the/DT
mutation/NN
of/IN
IDH2/NN
has/VBZ
a/DT
function/NN
to/TO
bind/VB
with/IN
its/PRP$
substrate/NN
,/,
so/RB
the/DT
substitutions/NNS
of/IN
the/DT
residue/NN
decrease/NN
the/DT
binding/NN
affinity/NN
with/IN
the/DT
substrate/NN
./.
====================
The/DT
protein/NN
region/NN
frame-shifted/VBD
by/IN
the/DT
mutation/NN
of/IN
NPM1/NN
is/VBZ
related/JJ
to/TO
the/DT
function/NN
of/IN
nuclear/JJ
localization/NN
,/,
important/JJ
for/IN
maintaining/VBG
the/DT
structure/NN
./.
====================
The/DT
structural/JJ
modeling/VBG
of/IN
RASGEF1B/NN
shows/VBZ
that/IN
the/DT
mutated/VBN
residue/NN
Arg261/NN
generates/VBZ
a/DT
new/JJ
hydrogen/NN
bond/NN
with/IN
Asn303/NN
,/,
affecting/VBG
the/DT
stretch/NN
of/IN
neighbor/JJ
helical/JJ
structures/NNS
./.
====================
The/DT
protein/NN
structure/NN
of/IN
MSH4/NN
shows/VBZ
that/IN
the/DT
salt/NN
bridge/NN
between/IN
Glu415/NN
and/CC
Arg474/NN
is/VBZ
essential/JJ
for/IN
the/DT
folding/JJ
and/CC
stability/NN
of/IN
the/DT
protein/NN
structure/NN
but/CC
is/VBZ
broken/VBN
by/IN
the/DT
mutation/NN
(/(
Table/JJ
4/CD
,/,
Fig/NN
./.
====================
11/CD
)/)
./.
====================
We/PRP
have/VBP
analyzed/VBN
10/CD
exome/JJ
sequencing/NN
samples/NNS
and/CC
SNP/NN
chip/NN
data/NNS
using/VBG
a/DT
variety/NN
of/IN
bioinformatics/NNS
methods/NNS
./.
====================
According/VBG
to/TO
the/DT
concordance/NN
results/NNS
,/,
comparing/VBG
with/IN
SNP/NN
chip/NN
data/NNS
,/,
we/PRP
concluded/VBD
that/IN
the/DT
G10.N/NN
exome/JJ
sample/NN
is/VBZ
not/RB
the/DT
correct/JJ
pair/NN
./.
====================
Comparing/VBG
SNPs/NNS
between/IN
normal/JJ
and/CC
tumor/NN
pairs/NNS
revealed/VBD
that/IN
the/DT
normal-tumor/NN
pair/NN
of/IN
sample/JJ
G06/NN
was/VBD
not/RB
matched/VBN
,/,
and/CC
the/DT
G10/NN
exome/JJ
showed/VBD
abnormal/JJ
LOH/NN
in/IN
chrX/NN
but/CC
had/VBD
no/DT
somatic/JJ
mutation/NN
./.
====================
So/RB
,/,
we/PRP
had/VBD
removed/VBN
G06/NN
and/CC
G10/NN
for/IN
discovering/VBG
somatic/JJ
mutations/NNS
./.
====================
After/IN
removing/VBG
G06/NN
and/CC
G10/NN
,/,
with/IN
8/CD
paired-end/NN
samples/NNS
,/,
we/PRP
discovered/VBD
27/CD
functionally/RB
important/JJ
somatic/JJ
mutations/NNS
with/IN
significance/NN
./.
====================
They/PRP
included/VBD
well-known/JJ
genes/NNS
in/IN
AML/NN
,/,
such/JJ
as/IN
NPM1/NN
,/,
IDH2/NN
,/,
GATA2/NN
,/,
and/CC
CEBPA/NN
./.
====================
Especially/RB
,/,
NPM1/NN
and/CC
GATA2/NN
were/VBD
found/VBN
in/IN
2/CD
out/RP
of/IN
8/CD
samples/NNS
./.
====================
In/IN
sample/NN
G05/NN
,/,
we/PRP
found/VBD
one/CD
abnormal/JJ
region/NN
at/IN
chr1/NN
and/CC
an/DT
LOH/NN
region/NN
at/IN
chr13/NN
./.
====================
We/PRP
could/MD
conclude/VB
that/IN
the/DT
LOH/NN
region/NN
could/MD
potentially/RB
make/VBP
a/DT
fusion/NN
gene/NN
by/IN
INTS6/NN
and/CC
KIAA1704/NN
,/,
and/CC
we/PRP
did/VBD
further/RBR
network/NN
analysis/NN
on/IN
that/DT
./.
====================
The/DT
results/NNS
of/IN
IPA/NN
analysis/NN
gave/VBD
``/CD
Cell/NN
Death/NN
and/CC
Survival/NN
,/,
Cell/NN
Cycle/NN
''/CD
network/NN
as/IN
the/DT
top/NN
network/NN
,/,
and/CC
it/PRP
includes/VBZ
GATA2/NN
and/CC
MAST2/NN
(/(
somatic/JJ
mutation/NN
)/)
./.
====================
We/PRP
had/VBD
done/RB
IPA/NN
analysis/NN
with/IN
26/CD
genes/NNS
,/,
giving/VBG
the/DT
``/NN
Cancer/NN
,/,
Hematological/JJ
Disease/NN
,/,
Cell/NNP
Cycle/NN
Network/NN
''/NNP
as/IN
the/DT
top/NN
network/NN
,/,
and/CC
it/PRP
includes/VBZ
NPM1/NN
,/,
GATA2/NN
,/,
and/CC
CEBPA/NN
,/,
which/WDT
are/VBP
well-known/JJ
driver/RB
genes/NNS
in/IN
AML/NN
[/(
3/CD
]/)
./.
====================
Since/IN
those/DT
3/CD
genes/NNS
have/VBP
many/JJ
edges/NNS
in/IN
the/DT
result/NN
,/,
we/PRP
could/MD
conclude/VB
that/IN
those/DT
genes/NNS
are/VBP
indirect/JJ
evidence/NN
of/IN
driver/RB
genes/NNS
./.
====================
The/DT
second/JJ
network/NN
is/VBZ
related/JJ
with/IN
``/NN
Cell/NN
Death/NN
and/CC
Survival/NN
,/,
''/NNP
and/CC
it/PRP
includes/VBZ
IDH2/NN
and/CC
PHF6/NN
genes/NNS
,/,
the/DT
same/JJ
as/IN
G05/NN
's/POS
top/NN
network/NN
./.
====================
So/RB
far/RB
,/,
our/PRP$
conclusion/NN
is/VBZ
that/DT
8/CD
samples/NNS
are/VBP
related/JJ
with/IN
the/DT
``/NN
Cancer/NN
,/,
Hematological/JJ
Disease/NN
,/,
Cell/NN
Cycle/NN
Network/NN
''/CD
but/CC
sample/JJ
G05/NN
is/VBZ
related/JJ
with/IN
the/DT
``/NN
Cell/NN
Death/NN
and/CC
Survival/NN
Network/NN
./.
''/CD
====================
We/PRP
had/VBD
searched/VBN
previous/JJ
works/NNS
of/IN
genome-wide/NN
somatic/JJ
mutation/NN
discovery/NN
and/CC
concluded/VBD
that/IN
8/CD
exome/JJ
samples/NNS
might/MD
be/VB
AML/NN
./.
====================
Somatic/JJ
mutation/NN
profiles/NNS
of/IN
blood/NN
cancer/NN
are/VBP
summarized/VBN
in/IN
Table/JJ
5/CD
[/(
3/CD
,/,
9/CD
,/,
10/CD
]/)
./.
====================
But/CC
,/,
we/PRP
could/MD
not/RB
find/VB
any/DT
somatic/JJ
mutations/NNS
in/IN
the/DT
FLT3/NN
or/CC
RAS/NN
gene/NN
./.
====================
Chronic/JJ
lymphocytic/JJ
leukemia/NN
and/CC
Blast/NN
Crisis/NN
chronic/JJ
myeloid/JJ
leukemia/NN
did/VBD
not/RB
have/VB
somatic/JJ
mutations/NNS
in/IN
NPM1/NN
or/CC
CEBPA/NN
./.
====================
Seven/CD
out/RP
of/IN
8/CD
samples/NNS
showed/VBD
neither/CC
LOH/NN
nor/CC
SCNA/NN
,/,
so/RB
we/PRP
could/MD
conclude/VB
that/IN
those/DT
patients/NNS
had/VBD
a/DT
normal/JJ
karyotype/NN
with/IN
no/DT
translocation/NN
or/CC
inversion/NN
./.
====================
If/IN
possible/JJ
,/,
additional/JJ
RNA-Seq/NN
experiments/NNS
or/CC
another/DT
technique/NN
can/MD
provide/VB
enough/JJ
evidence/NN
of/IN
karyotypes/NNS
of/IN
those/DT
samples/NNS
./.
====================
In/IN
CEBPA/NN
,/,
IDH2/NN
,/,
and/CC
NPM1/NN
,/,
we/PRP
saw/VBP
somatic/JJ
mutations/NNS
located/JJ
in/IN
helix/NN
regions/NNS
./.
====================
By/IN
using/VBG
protein/NN
structure/NN
modeling/VBG
,/,
we/PRP
found/VBD
that/IN
IDH2/NN
,/,
RASGEF1B/NN
,/,
and/CC
MSH4/NN
could/MD
have/VB
structural/JJ
variations/NNS
,/,
affecting/VBG
protein/NN
functions/VBZ
./.
====================
Somatic/JJ
mutations/NNS
in/IN
IDH2/NN
could/MD
break/NN
hydrogen/NN
bonds/NNS
./.
====================
Bioinformatics/NNS
pipeline/NN
for/IN
exome/JJ
data/NNS
and/CC
numbers/NNS
of/IN
somatic/JJ
mutation/NN
candidates/NNS
for/IN
each/DT
filtering/VBG
step/NN
./.
====================
SNP/NN
,/,
single/JJ
nucleotide/NN
polymorphism/NN
;/:
LOH/NN
,/,
loss/NN
of/IN
heterozygosity/NN
;/:
SCNA/NN
,/,
somatic/JJ
copy-number/NN
alterations/NNS
;/:
SCHALE/NN
,/,
somatic/JJ
copy-number/NN
and/CC
heterozygosity/NN
alteration/NN
estimation/NN
;/:
NS/SS/I/NN
,/,
nonsense/JJ
,/,
splice-site/NN
,/,
or/CC
coding/VBG
indel/NN
mutations/NNS
./.
====================
Somatic/JJ
copy-number/NN
and/CC
heterozygosity/NN
alteration/NN
estimation/NN
(/(
SCHALE/NN
)/)
,/,
developed/VBD
for/IN
detection/NN
of/IN
loss/NN
of/IN
heterozygosity/NN
(/(
LOH/NN
)/)
and/CC
somatic/JJ
copy-number/NN
alterations/NNS
(/(
SCNA/NN
)/)
./.
====================
TMM/NN
,/,
trimmed/VBD
mean/NN
of/IN
M/NN
values/NNS
;/:
CBS/NN
,/,
circular/JJ
binary/NN
segmentation/NN
./.
====================
Changes/NNS
in/IN
loss/NN
of/IN
heterozygosity/NN
and/CC
somatic/JJ
copy-number/NN
alteration/NN
in/IN
sample/NN
G10/NN
./.
====================
Abnormal/JJ
region/NN
on/IN
chr1/NN
in/IN
G05/NN
./.
====================
LOH/NN
,/,
loss/NN
of/IN
heterozygosity/NN
;/:
SNP/NN
,/,
single/JJ
nucleotide/NN
poymorphism/NN
;/:
CNA/NN
,/,
copy-number/NN
alteration/NN
./.
====================
Loss/NN
of/IN
heterozygosity/NN
on/IN
chr13/NN
in/IN
G05/NN
./.
====================
Genes/NNS
in/IN
a/DT
loss/NN
of/IN
heterozygosity/NN
region/NN
./.
====================
Image/NN
adopted/JJ
from/IN
University/JJ
of/IN
California/NN
Santa/NN
Cruz/NN
(/(
UCSC/NN
)/)
Genome/NN
Browser/NN
,/,
chr5:45,578,409-52,035,344/NN
./.
====================
Ingenity/NN
Pathway/NN
Analysis/NN
(/(
IPA/NN
)/)
from/IN
genes/NNS
with/IN
loss/NN
of/IN
heterozygosity/NN
and/CC
somatic/JJ
mutation/NN
(/(
sample/NN
G05/NN
)/)
./.
====================
Data/NNS
were/VBD
analyzed/VBN
through/IN
the/DT
use/NN
of/IN
IPA/NN
(/(
Ingenuity®/NNP
Systems/NNS
,/,
http/NN
:/:
//www.ingenuity.com/JJ
)/)
[/(
8/CD
]/)
./.
====================
``/CD
Cancer/NN
,/,
Hematological/JJ
Disease/NN
,/,
Cell/NN
Cycle/NN
''/CD
Network/NN
./.
====================
Data/NNS
were/VBD
analyzed/VBN
through/IN
the/DT
use/NN
of/IN
Ingenity/NN
Pathway/NN
Analysis/NN
(/(
IPA/NN
)/)
(/(
Ingenuity®/NNP
Systems/NNS
,/,
http/NN
:/:
//www.ingenuity.com/JJ
)/)
[/(
8/CD
]/)
./.
====================
Major/JJ
interaction/NN
in/IN
top/NN
network/NN
./.
====================
Data/NNS
were/VBD
analyzed/VBN
through/IN
the/DT
use/NN
of/IN
Ingenity/NN
Pathway/NN
Analysis/NN
(/(
IPA/NN
)/)
(/(
Ingenuity®/NNP
Systems/NNS
,/,
http/NN
:/:
//www.ingenuity.com/JJ
)/)
[/(
8/CD
]/)
./.
====================
``/CD
Cell/NN
Death/NN
and/CC
Survival/NN
,/,
Cell/NN
Cycle/NN
,/,
Cell-to-Cell/NN
Signaling/NN
and/CC
Interaction/NN
,/,
Cellular/JJ
Movement/JJ
''/CD
Network/NN
./.
====================
Data/NNS
were/VBD
analyzed/VBN
through/IN
the/DT
use/NN
of/IN
Ingenity/NN
Pathway/NN
Analysis/NN
(/(
IPA/NN
)/)
(/(
Ingenuity®/NNP
Systems/NNS
,/,
http/NN
:/:
//www.ingenuity.com/JJ
)/)
[/(
8/CD
]/)
./.
====================
Location/NN
of/IN
somatic/JJ
mutation/NN
in/IN
protein/NN
structure/NN
./.
====================
(/(
A/NN
)/)
IDH2/NN
./.
====================
(/(
B/NN
)/)
RASGEF1B/NN
./.
====================
(/(
C/NN
)/)
MSH4/NN
./.
====================
A/DT
list/NN
of/IN
functionally/RB
important/JJ
somatic/JJ
mutations/NNS
in/IN
8/CD
samples/NNS
====================
Two/CD
top/NN
networks/NNS
inferred/VBD
from/IN
Ingenuity/NN
Pathway/NN
Analysis/NN
====================
Protein/NN
residues/NNS
in/IN
which/WDT
somatic/JJ
mutation/NN
is/VBZ
located/JJ
====================
Protein/NN
structure/NN
modeling/VBG
====================
Somatic/JJ
mutation/NN
profile/NN
of/IN
three/CD
leukemia/NN
studies/NNS
====================
